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EXPERIENCE AND REASON—Briefly Recorded
‘‘In Medicine one must pay attention not to plausible theorizing but to experience and reason together. . . . I
agree that theorizing is to be approved, provided that it is based on facts, and systematically makes its
deductions from what is observed. . . . But conclusions drawn from unaided reason can hardly be serviceable;
only those drawn from observed fact.’’ Hippocrates: Precepts. (Short communications of factual material are
published here. Comments and criticisms appear as letters to the Editor.)
Functional Hyperactivity of Hepatic
Glutamate Dehydrogenase as a
Cause of the Hyperinsulinism/
Hyperammonemia Syndrome:
Effect of Treatment
ABSTRACT. Objective. The combination of persis-
tent hyperammonemia and hypoketotic hypoglycemia in
infancy presents a diagnostic challenge. Investigation of
the possible causes and regulators of the ammonia and
glucose disposal may result in a true diagnosis and pre-
dict an optimum treatment.
Patient. Since the neonatal period, a white girl had
been treated for hyperammonemia and postprandial hy-
poglycemia with intermittent hyperinsulinism. Her
blood level of ammonia varied from 100 to 300 mmol/L
and was independent of the protein intake.
Methods. Enzymes of the urea cycle as well as glu-
tamine synthetase and glutamate dehydrogenase (GDH)
were assayed in liver tissue and/or lymphocytes.
Results. The activity of hepatic GDH was 874 nmol/
(minzmg protein) (controls: 472–938). Half-maximum in-
hibition by guanosine triphosphate was reached at a
concentration of 3.9 mmol/L (mean control values: .32).
The ratio of plasma glutamine/blood ammonia was un-
usually low. Oral supplements with N-carbamylgluta-
mate resulted in a moderate decrease of the blood level of
ammonia. The hyperinsulinism was successfully treated
with diazoxide.
Conclusion. A continuous conversion of glutamate to
2-oxoglutarate causes a depletion of glutamate needed
for the synthesis of N-acetylglutamate, the catalyst of
the urea synthesis starting with ammonia. In addition,
the shortage of glutamate may lead to an insufficient
formation of glutamine by glutamine synthetase. As
GDH stimulates the release of insulin, the concomi-
tant hyperinsulinism can be explained. This disorder
should be considered in every patient with postprandial
hypoglycemia and diet-independent hyperammonemia.
Pediatrics 2000;106:596–600; hyperammonemia, hyperin-
sulinism, plasma glutamine, glutamate dehydrogenase.
ABBREVIATIONS. HIHA, hyperinsulinism/hyperammonemia;
GDH, glutamate dehydrogenase; GTP, guanosine triphosphate;
CG, carbamylglutamate; ADP, adenosine diphosphate; CSF, cere-
brospinal fluid.
Neonatal or infantile hypoketotic hypoglyce-mia with persistent hyperammonemia hasbeen associated with only a few inherited
conditions, ie, either defects of the carnitine transport
system such as carnitine acylcarnitine carrier defi-
ciency1 or unusual forms of hyperinsulinism.2 In
affected patients coma and/or convulsions may rap-
idly develop. Therefore, immediate adequate treat-
ment is required.
The more common cases of isolated hyperinsulin-
ism may be the result of genetic defects in the insulin
secretion by the pancreatic b cells.3 These defects
may reside in the plasma membrane sulfonylurea
receptor (SUR 1) or an associated potassium channel
(Kir 6.2) of the pancreatic b cells. Other causes of
hyperinsulinism have also been described. These
classic types of hyperinsulinism are not accompanied
by elevated blood ammonia levels.
Recently, 10 patients with hyperinsulinism com-
bined with hyperammonemia (HIHA) have been de-
scribed.2,4–10 Both sporadic and dominantly inher-
ited cases were observed. The clinical histories more
or less resembled those of leucine-sensitive hypogly-
cemia,11 although disorders related with the ammo-
nia disposal have not been reported in the latter
condition. The HIHA syndrome has been studied in
lymphoblasts. This syndrome was shown to be either
the result of hyperactivity of glutamate dehydroge-
nase (GDH)10 or impaired inhibition of GDH by
guanosine triphosphate (GTP).5 GDH catalyzes the
conversion of glutamic acid into 2-oxoglutaric acid.
In this article, we report our attempts to treat a
patient with HIHA in whom the primary defect
could be established in liver tissue.
CASE REPORT
The female patient was born as the second child of healthy,
nonconsanguineous parents after an uneventful pregnancy and
delivery. Neither parent had ever experienced protein intolerance
or a tendency to hypoglycemia. Her birth weight was 3840 g (75th
centile [P75]), head circumference 36 cm (P75), and Apgar score
8/9. She was admitted on the twelfth day of life because of
convulsions and cyanosis, associated with hypoglycemia. During
the hypoglycemic episodes, which recurred after discontinuing
the parenteral glucose supply, no ketone bodies were found in the
urine. Hyperinsulinism was diagnosed on the finding of insulin
levels of 28 and 45 mU/L at glucose concentrations of 2.8 and 2.7
mmol/L, respectively. When measured at low blood glucose lev-
els, the 24-hour C-peptide excretion was 8.1 nmol (controls: 1.0–
5.5). Blood ammonia was repeatedly elevated and varied from 100
to 200 mmol/L in the initial period (neonatal controls ,80). All
other routine clinical chemical analyses were normal.
An electroencephalogram did not show any epileptic changes,
a computed tomography scan was performed at the age of 2
months and revealed widened ventricles as well as hypodensities
of the frontotemporal white matter.
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Feeding difficulties became a major clinical problem, necessi-
tating gavage feeding from the age of 6 weeks. She was discharged
at 14 weeks. At that time, treatment consisted of diazoxide (2 3 8
mg/day), a high-carbohydrate, and a protein-restricted diet [1.5
g/(kgzday)]. Arginine (and later citrulline, 5 3 1000 mg/day) and
sodium benzoate (4 3 1500 mg/day) were administered to reduce
the blood ammonia levels.
At the age of 2 years, the patient was referred to the University
Children’s Hospital and her condition was reevaluated. Her
length was 84.5 cm (50th centile [P50]), body weight was 15 kg
(.P90), and head circumference was 48 cm (P50). Her motor
development was 7 months delayed; she showed a marked retar-
dation of speech development. Blood ammonia was 312 mmol/L
(controls: ,50); no further clues to a diagnosis were found. De-
spite the high ammonia levels no clinical signs of hyperammone-
mia were noted (such as drowsiness, lethargy or ataxia). A brief
trial with an extreme dietary protein restriction [.5 g/(kgzday)] did
not have any effect on the ammonia levels. Plasma-free carnitine
was 12 mmol/L (controls: 25–60), total carnitine 13 mmol/L (con-
trols: 30–65). Carnitine supplements (2 3 750 mg/day) were
administered. The treatment was adjusted by replacing the oligo-
glucose formula by uncooked cornstarch. Over the years, the
diazoxide treatment was gradually adjusted to the requirements,
reaching a dose of 4 3 50 mg/day at the age of 6 years.
As a result of the mitigated carbohydrate intake and the result-
ing decrease of fat deposits, the patient’s adipose appearance
markedly improved. However, her development showed a slow
progress and the feeding difficulties persisted. These problems led
to the decision to install a gastrostoma at age 5. During this
intervention, a surgical liver biopsy was taken for diagnostic
purposes. After the final diagnosis, treatment with oral supple-
ments of carbamylglutamate (CG) (4 3 500 mg/day) was started.
Blood ammonia levels tended to be lower on this regimen, but did
not normalize completely. At the age of 6.5 years, her psychomo-
tor development was estimated to be at a level of 4.5 to 5 years (not
formally tested).
MATERIALS AND METHODS
Quantitative amino acid analysis was performed with a Bio-
chrom 20 amino acid analyzer (Amersham Pharmacia Biotech,
Cambridge, United Kingdom). Organic acids in urine were ana-
lyzed by gas chromatography/mass spectrometry (MD800,
Fisons, Manchester, United Kingdom) of the ethoximated methyl
esters after ethylacetate extraction. Orotic acid in urine was mea-
sured using a colorimetric assay.12 Profiling of plasma acylcar-
nitines was performed by fast-atom bombardment mass spectrom-
etry after solid-phase extraction and butyl ester formation.13 All
other clinical chemical analyses, including all aspects of insulin
homeostasis, were performed by standard methods.
Glutamine synthetase activity was assayed in lymphocytes,
leukocytes, and liver homogenate of the patient according to
Rowe14 with slight modifications. The synthesis of 1-14C-glu-
tamine from 10 mM 1-14C-potassium glutamate was measured.
The reaction mixture contained 10 mM phosphoenolpyruvate, 50
mM imidazole-hydrochloric acid (pH 7.2), 10 mM 2-mercaptoetha-
nol, 1 mM ethylenediaminetetraacetic acid (pH 7.2), 20 mM
NH4Cl, 20 mM MgCl2, 10 mM sodium adenosine triphosphate
(pH 7.4), 5 mg (1 IU) pyruvate kinase and 3 mM rotenone. The total
volume was 100 mL; incubation at 37°C was conducted for 30 or 60
minutes. After stopping the reaction with 400 mL of ice cold 4 mM
imidazole-HCl (pH 7.2) plus 10 mM glutamine, the reaction prod-
uct was isolated on a .5 3 7 cm AG-1x8 (200–400 mesh) ion
exchange column, which was in the acetate form. GDH activity
was assayed in a liver biopsy homogenate, essentially as described
by Wreszcynski and Colman.15 The reaction of 2-oxoglutarate
with ammoniumchloride forming glutamate and the simultaneous
oxidation of NADH was followed spectrophotometrically at 340
nm. Stimulation of the enzyme activity was achieved by adding
200 mM adenosine diphosphate (ADP), whereas the effects of the
regulatory GTP were studied at concentrations of .01 to 10.0 mM.
Ornithine carbamoyltransferase and carbamoyl phosphate syn-
thetase activities were measured in a liver biopsy specimen by
spectrophotometric methods.
RESULTS
Because of the persistent hyperammonemia, de-
tailed studies of the urea cycle were performed. Both
fasting and postprandial plasma and urine amino
acid concentrations were always normal. In particu-
lar, citrulline, arginine, and ornithine were not de-
creased, However, the ratio of plasma glutamine ver-
sus blood ammonia was unusually low (Fig 1),
unlike that observed in patients with various urea
cycle defects.16 Plasma glutamate averaged 54 6 25
mmol/L (controls: 30 6 14), and was therefore not
decreased. Urinary orotic acid excretions were incon-
sistent; at no occasion did we find a striking increase.
Urinary organic acids, including 2-oxoglutarate,
have always been normal. Cerebrospinal fluid (CSF)
amino acids revealed a normal glutamine level (421,
732, and 800 mmol/L on 3 occasions, controls: 614 6
241) and markedly increased levels of ammonia (100,
149 and 161 mmol/L, controls ,11). The patient was
treated with various regimens aimed at reducing the
ammonia level. Neither a drastic reduction of the
dietary protein to .5 g/(kgzday), nor supplementa-
tion with sodium benzoate and arginine or citrulline,
led to changes of blood ammonia levels (Fig 2). In
addition, treatment with neomycin remained with-
out effect (data not shown).
At various occasions, simultaneous measurements
of blood glucose and insulin were performed, clearly
indicating hyperinsulinism. Early morning blood
glucose was always in excess of 3 mmol/L; glucose
levels during the day went down to 2.7 mmol/L with
a concomitant insulin of 45 mU/L. On one occasion,
blood glucose and insulin were checked before and
after a meal. Glucose was 2.8 mmol/L before and 3.5
mmol/L 2 hours after the meal; simultaneous insu-
lins were 28 and 101 mU/L, respectively.
The activities of hepatic carbamoyl phosphate syn-
thetase and ornithine carbamoyl transferase were 463
nmol/(hzmg protein) (control: 587) and 36.9 mmol/
(hzmg protein) (control: 45.5), respectively; both val-
ues were normal. Glutamine synthetase was assayed
in leukocytes and liver, which resulted in values of
Fig 1. Relationships between blood ammonia and plasma glu-
tamine in a patient with a regulatory defect of GDH on conven-
tional treatment (), on treatment with CG (), and in some
patients with ornithine carbamoyltransferase deficiency (l).
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.175 nmol/(minzmg protein) and 7.15 nmol/(minzmg
wet weight) respectively. Control values for leuko-
cytes and liver were .115 and 3.41, respectively.
The results of the GDH assay in liver are shown in
Fig 3. Under standard conditions with ADP stimula-
tion, the patient had a normal activity [874 nmol/
(minzmg protein), controls 472–938 (n 5 3)]. After
addition of the inhibitor GTP, this activity decreased
more slowly than in the control. Half-maximum in-
hibition was reached at a GTP concentration of 3.9
mmol/L (control mean: .32). Histologically, the liver
tissue was normal; there were minimal signs of fi-
brosis. GDH in fibroblasts was normal [19.4 nmol/
(minzmg protein); controls 7.9–26.8 (n 5 3)]. The GTP
inhibition was not tested in these cells.
Following the diagnosis, the patient was given a
trial with oral CG (4 3 500 mg/day). This treatment
was based on the hypothesis that she might suffer
from a shortage of glutamate necessary for the syn-
thesis of N-acetylglutamate. Blood ammonia levels
were regularly checked during 10 months of fol-
low-up and were found to be consistently lower than
before the onset of the treatment (Fig 2).
DISCUSSION
Recurrent periods of hypoglycemia in infancy
without the concurrent availability of alternative
energy substrates such as ketone bodies or lactate,
represents one of the most important metabolic ab-
normalities in young children. The same applies for
hyperammonemia. A relatively mild increase of
blood ammonia levels for short periods of time pre-
sumably leads to cerebral damage. Our patient, hav-
ing only a moderate mental retardation, has had
hyperammonemia with ammonia levels in blood and
CSF of 100 to 300 mmol/L for 6 years in combination
with episodically occurring nonfasting hypoketotic
hypoglycemia. The latter was in fact the first present-
ing symptom, accompanied by convulsions. Subse-
quently hyperinsulinism was diagnosed and this was
Fig 2. Blood ammonia levels in a patient with a reg-
ulatory defect of GDH under various regimens of
treatment without () and with () CG. No influence
whatsoever of the amount of dietary protein could be
observed. At this point the CG treatment had been
given for 10 months.
Fig 3. Inhibition of GDH by GTP in a liver homogenate. For comparison the basal activities of a patient with a regulatory defect of this
enzyme (1) and three controls (F) were made to match. Absolute values of the basal activities are in the text.
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treated successfully with diazoxide. It was clearly
shown that the hypoglycemias were most prominent
after a protein-containing meal, similar to the obser-
vations made in leucine-sensitive hypoglycemia.11
As there were no diagnostic clues to the hyperam-
monemia, treatment was originally directed at alle-
viating the symptoms by administrating citrulline
(originally arginine) for stimulation of the urea cycle,
and sodium benzoate for the direct removal of am-
monia in the form of hippurate. When we found the
aberration in the GDH, implying that in this patient
the function of the urea cycle was not compromised,
conventional treatment was stopped, and replaced
by CG treatment.
Recently, the HIHA syndrome has been identi-
fied.2 Not long thereafter, Stanley et al5 disclosed
regulatory mutations of the GDH gene in some of the
patients. Thus far, 3 out of 10 patients, whose clinical
history has been published, showed the GDH insen-
sitivity toward GTP in lymphoblasts. The patient
reported by Yorifuji et al10 had a different mutation
resulting in a permanent hyperactivity of GDH. No
studies in liver were reported. Our data originating
from liver tissue show that the basal GDH activity in
the patient was normal, in accordance with the lym-
phoblast findings in sporadic cases.5 In contrast, the
basal GDH-activity in familial cases was moderately
decreased. The half-maximum inhibitory concentra-
tion of GTP in the patient’s liver was approximately
10-fold higher than in control liver tissue. This dif-
ference was more pronounced than previously found
in the patients’ lymphoblasts.5 Presumably, GTP is
present in hepatic tissue at a level that is sufficient to
inhibit normal GDH. Mutant GDH—needing a much
higher concentration of GTP for its inactivation—is
supposed to be fully active when the GTP level is not
decreased. There are only a few conditions in which
the intracellular GTP concentrations are decreased,
eg, hypoxanthine phosphoribosyltransferase defi-
ciency (Lesch-Nyhan syndrome) or purine nucleo-
side phosphorylase deficiency. Neither of these con-
ditions is associated with a deranged GDH activity
leading to hyperinsulinism or hyperammonemia.
Hepatic glutamine synthetase activity in our pa-
tient’s liver was increased. This may be considered as
a compensatory mechanism for the removal of am-
monia. However, glutamine synthetase is a high-
affinity, low-capacity enzyme and is apparently not
capable of removing all excess ammonia. The CSF
ammonia levels in our patient were quite high, al-
though accompanied by normal glutamine levels.
This result again raises the question of ammonia/
glutamine toxicity to the brain. We have the impres-
sion that a single elevation of brain ammonia—with-
out glutamine—showed a less deleterious effect on
the brain than a combined increase. Hyperammone-
mic rats, treated with the glutamine synthetase in-
hibitor methionine sulfoximine, had less brain
edema than untreated hyperammonemic rats.17
Other reports have shown that brain glutamine syn-
thetase is a saturable enzyme and that ammonia
encephalopathy progresses only after saturation of
this enzyme.18 It remains to be established whether
brain glutamine synthetase in the present patient
was actually exhausted. We do not have information
about CSF ammonia levels in patients with urea
cycle defects.
The clinical spectrum of HIHA, as deduced from
our patient and the literature,2,4–10 is rather uniform.
None of the patients was severely retarded. In gen-
eral, moderate mental retardation or even normal
development was reported. Convulsions—possibly
the result of hypoglycemia—were invariably the pre-
senting symptom. Although symptoms are expected
to start in the first week of life, most patients were
detected between 2 and 7 months. Blood ammonia
levels were comparable in all patients, ranging from
75 to 350 mmol/L. None of the authors reported
abnormalities of plasma amino acid profiles. There
were 2 reports on increased 2-oxoglutarate levels in
the urine.8,9 It was not mentioned whether these
patients had a decreased sensitivity of GDH inhibi-
tion by GTP. So there seems to be some biochemical
heterogeneity of the HIHA syndrome. Thus far, all
patients with a proven defect of GDH had a normal
2-oxoglutarate excretion, including the patient with
a permanent hyperactivity of GDH reported by
Yorifuji et al.10
Treatment of the hyperinsulinism varied from sim-
ple diazoxide administration (as in the present pa-
tient) to subtotal pancreatectomy. It has been shown
that glutamate stimulates insulin secretion in rats.19
The mechanism of this reaction is not entirely clear,
but an enhanced oxidation of glutamate by GDH
may be a contributing factor.5 Recently, it has been
shown that insulin secretion can be stimulated by
leucine, which activates GDH.20
The differential diagnosis of infantile nonketotic
hypoglycemia has been extended. It is now clear that
in every case of suspected hyperinsulinism blood
ammonia levels should be determined, preferably
together with plasma amino acids. The HIHA syn-
drome may prove to be less rare than originally
believed.
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Herbal Vitamins: Lead Toxicity and
Developmental Delay
ABSTRACT. A case of lead poisoning from an Indian
herbal vitamin is presented. The patient who was devel-
opmentally delayed was given an herbal vitamin from
India to strengthen his brain. The tablet contained large
amounts of lead and mercury, leading to significant lead
burden. Vulnerability of families and lack of awareness
of health care professionals of dangers of unknown
herbal supplementation are discussed. Pediatrics 2000;
106:600–602; herbal vitamins, lead poisoning, develop-
mental delay.
ABBREVIATIONS. EDTA, ethylenediaminetetraacetic acid; BAL,
dimercoprol.
Low levels of lead ingestion can lead to cogni-tive deficits and even long-lasting neurodevel-opmental deficits.1 In the United States the
most common source of lead is paint, whereas, in
other countries, folk remedies are a significant
source.2 Families with developmentally delayed chil-
dren are always seeking ways to improve their
child’s status. This quest makes families especially
vulnerable to nonstandard medical intervention and
to folk remedies. Many immigrant families are accul-
turated to non-American remedies. Many of these
products have become available and are being used
in the United States.
We present a case of chronic lead poisoning in the
United States in an Indian child who had an estab-
lished neurodevelopmental delay. His mother was
giving him a natural medication to strengthen his
brain.
CASE REPORT
S.P. is a 5-year-old Indian boy with static encephalopathy,
seizures, and developmental delay from neonatal asphyxia. He
was referred to a hematologist for persistent anemia (hemoglobin:
9.2 g/dL) without basophilic stippling, refractory to iron therapy.
Initial investigation revealed normal iron stores and normal he-
moglobin electrophoresis. To complete the workup, a blood lead
level was obtained, which was 86 mg/dL. He was admitted to
Childrens Hospital Los Angeles for chelation with calcium diso-
dium ethylenediaminetetraacetic acid (EDTA) and dimercoprol
(BAL). On physical examination he was alert and active but
nonverbal. He was able to stand with support but not ambulate
and had no focal neurologic defects. Skeletal and abdominal
radiographs revealed no lead lines and no gastric lead particles.
His lead level at the end of the chelation was 25.6 mg/dL. A
24-hour-urine collection (1245 mL) on day 3 of chelation revealed
a lead level of 4480 mg/L or 5578 mg/24-hour (normally none
detectable).
The mother who is well-educated and whose English is excel-
lent, initially denied any exposure to lead or use of any folk
medications. On further investigation, the mother had been giving
S.P. a Tibetan Herbal Vitamin, in the form of tablets, 3 times per
day for the past 4 years of his life. A traditional medicine healer
told the parents that these tablets were pure medicinal herbs and
plants that were prepared according to ancient Tibetan pharma-
cological traditions. These tablets were said to be free from any
harmful or toxic substances and would actually promote brain
growth and improve his mental capabilities. The tablets were
produced in India and each was individually wrapped (Fig 1). The
tablets were analyzed by the Los Angeles County Environmental
Toxicology Laboratory for lead, arsenic, cadmium and mercury
content (Table 1). It was estimated that S.P. ingested approxi-
mately 63 g of lead over the 4-year period. The radiographs of the
tablets (Fig 2) were consistent with high lead and mercury content.
The 24-hour-urine sample (1245 mL) was also analyzed for mer-
cury (23 mg/L; 28.64 mg/24-hour) and arsenic (undetectable).
Blood level of mercury was undetectable at ,.5 mg/dL, and blood
arsenic was .2 mg/dL (range: 0–3.0 mg/dL). Public health inves-
tigation of the home was negative for other sources of lead.
He was followed as an outpatient and chelated with succimer
without incidence. Seven months after his first admission, his
Childrens Hospital Los Angeles is affiliated with the University of Southern
California, Keck School of Medicine.
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blood level was 76 mg/dL and he was readmitted for EDTA and
BAL chelation. On day 2 of chelation he had a 1-minute tonic
clonic seizure. On day 2 random urinary lead was 2310 mg/L and
his blood lead level on discharge was 41.3 mg/dL. During the next
4 years S.P. underwent a total of an additional 6 chelations with
succimer when his lead levels were .45 mg/dL. He had no other
complication of chelation and after 4 years, his latest lead level
was 24.5 mg/dL. He has maintained his growth parameters and
made developmental progress, achieving ambulation with mini-
mum assistance and he understands simple directions but remains
nonverbal.
DISCUSSION
Alternative medicine and folk remedies are widely
used and accepted by the general public. It is esti-
mated that in 1990 $13.7 billion was spent on uncon-
ventional therapy.3 Many academic centers have
started programs to study and teach the use of alter-
native forms of therapy. When traditional therapies
and medications cannot cure or significantly im-
prove a chronic condition, families and patients are
motivated to try alternative approaches. Children
with developmental disabilities are especially vul-
nerable to the introduction of alternative therapies
and medications. Past movements such as megavita-
min therapy for retardation4 and the Doman-Dela-
cato technique for brain-damaged children5 are ex-
amples of alternative interventions which were
widely used in the United States without proven
efficacy. Families in ethnic communities that have a
tradition of alternative medicine and folk remedies
will seek and support their use and availability in the
community.
In our patient’s case, the pressure on the family to
use traditional medication arose from both the im-
mediate family and from the community that had a
great deal of experience and faith in the use of tra-
ditional medications from India. In discussing this
with the mother, the perceived efficacy of these in-
dividually wrapped and colorful vitamins was en-
hanced by their designation as a Tibetan herbal med-
ication.
In India, a form of traditional medicine called
Ayurveda is usually made of vegetable products,
occasionally from animal products and less often
from metals and minerals.2 The metals usually con-
sist of lead, mercury, arsenic or, rarely, gold. Analy-
sis of the patients’ tablets demonstrated a variable
and inconsistent amount of lead and mercury in each
tablet. Although previous reports have identified In-
dian herbal medications as a source of lead, mercury,
and arsenic poison, this is not widely appreciated by
the lay population or medical community.6–9 The
vitamins had been obtained directly from a relative
in India, costing approximately $40 for a 3-month
supply. The mother was told it was formulated by a
physician who was close to the Dalai Lama. The
mother was very compliant with all traditional ther-
apeutic interventions as she was with administering
and securing a steady supply of the vitamin.
S.P.’s baseline developmental delay made the de-
tection of the lead toxicity especially difficult. The
effect of lead exposure during brain development
has been well-documented.1 The impact on S.P. of
this level of toxicity over 4 years, in the context of a
prior neonatal asphyxia, is not quantifiable. Two
months after chelation the patient was able to walk
with minimal support and was more communica-
tive. Within 6 months of stopping the herbal vitamin,
and after chelation, his mother and grandmother felt
that he made significant progress in social interac-
tions characterized by more awareness and joy of
others, and responsiveness to directions. The persis-
tence of the high lead levels after multiple chelations
is not surprising given the estimated 63 g of lead
Fig 1. Individually wrapped vitamins.
TABLE 1. Analysis of Vitamins
Sample Lead mg/kg Mercury mg/kg
Tablet 1 35 300.0 12 800.0
Tablet 2 5 780.0 65.5
Tablet 3 54.8 3.0
Tablet 4 72.0 3.8
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ingested and the known half-life of lead in bone of
approximately 10 000 days.10
Physicians who treat diverse ethnic populations
need to become aware of traditional herbs as an
alternative treatment. There is also increasing use by
the general population of natural and folk remedies
as alternatives or enhancements to traditional medi-
cal interventions and prescriptions. Physicians need
to inquire about their use, and be knowledgeable
about benefits and risks. This awareness is especially
needed when working with families who have de-
velopmentally disabled children.
Cynthia Moore, MD*
Robert Adler, MD‡
*Division of General Pediatrics
‡Department of Pediatrics
Childrens Hospital Los Angeles
Los Angeles, CA 90027
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Human Granulocytic Ehrlichiosis
Presenting as Abdominal Pain
ABSTRACT. Human granulocytic ehrlichiosis (HGE) is
an emerging infectious disease that primarily affects
adults. Typical clinical features include fever, headache,
and myalgias. This case represents the youngest reported
patient with HGE. Her clinical presentation was unusual
in that she presented with severe abdominal pain. In
addition, she did not develop the typical spectrum of
laboratory abnormalities that has been reported in
adults. This patient’s course suggests that the presenta-
tion of HGE may be more varied than previously
reported. Pediatrics 2000;106:602–604; human granulo-
cytic ehrlichiosis, abdominal pain, acute abdomen, fever,
tick bite.
ABBREVIATIONS. HGE, human granulocytic ehrlichiosis; PCR,
polymerase chain reaction; IFA, indirect fluorescent antibody;
AST, aspartate aminotransferase; ALT, alanine aminotransferase;
CT, computed tomography (scan); IgG, immunoglobulin G; IgM,
immunoglobulin M.
Human granulocytic ehrlichiosis (HGE) is anemerging infectious disease caused by anorganism closely related or identical to Ehr-
lichia equi and E phagocytophilia.1,2 In the northeastern
United States the organism is transmitted by the deer
tick, Ixodes scapularis, which is the same vector that
transmits the cause of Lyme disease, Borrelia burgdor-
feri. In contrast to Lyme disease, however, HGE is
rare in patients ,20 years old and most cases occur
in males.3 Clinical features of the illness include fe-
Received for publication Oct 4, 1999; accepted Jan 27, 2000.
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Fig 2. Radiograph of vitamins.
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ver, headache, and myalgias, although there are no
consistent physical findings.4–6 Laboratory hall-
marks are neutropenia, thrombocytopenia, and
mildly elevated liver transaminases.
The diagnosis of HGE can be confirmed by finding
cytoplasmic inclusion bodies (morulae) in granulo-
cytes on a Wright-stained blood smear. Typically,
morulae are found in 1% to 6% of granulocytes,1
although a sensitivity as high as 80% has been re-
ported.6 Polymerase chain reaction (PCR) to the 16S
rDNA sequence has been shown to be rapid, sensi-
tive (86%), and specific (100%).7 However, PCR test-
ing is not widely available. At the present time, the
diagnosis of HGE is most often confirmed by either a
fourfold rise between acute and convalescent sera in
the indirect fluorescent antibody (IFA) titer to E equi
or a single titer $1:80.8
The following case is a very young patient with
HGE who had an unusual presentation with acute
abdominal pain.
CASE REPORT
A 5-year-old girl presented to the emergency department
with a 2-week history of fever and a 2-day history of abdominal
pain. There was no vomiting or diarrhea. Another physician
had begun treating her with amoxicillin 1 week before for
presumptive Lyme disease. There was no history of a tick bite
or erythema migrans and her Lyme antibody titers obtained at
that time were subsequently reported to be negative. In the
emergency department her physical examination was notable
for a temperature of 103°F and right lower quadrant tenderness
on deep abdominal palpation. Laboratory results included a
normal urinalysis, a hemoglobin of 11.2 g/dL, a hematocrit of
32%, a white blood count of 13 400/mm3 (59% neutrophils, 7%
bands, 26% lymphocytes with rare atypical forms, 7% mono-
cytes, and 1% eosinophils), and a platelet count of 287 000/
mm3. A blood culture was obtained. The pain resolved without
treatment and she was discharged.
She returned to the emergency department about 12 hours later
with a temperature of 103.6°F, pallor, abdominal distension, and
diffuse abdominal tenderness. A repeat complete blood count was
significant for a hemoglobin of 9.1 g/dL, a hematocrit of 27%, a
white blood cell count of 8000/mm3 (59% neutrophils, 5% bands,
26% lymphocytes, and 10% monocytes), and a platelet count of
278 000/mm3. The serum electrolytes, prothrombin time, partial
thromboplastin time, and a urinalysis were all normal. The aspar-
tate aminotransferase (AST) was minimally elevated (42 U/L), but
the alanine aminotransferase (ALT) was normal (36 U/L). Abdom-
inal radiographs and a computed tomography (CT) scan of the
abdomen with intravenous contrast were significant for mild hep-
atosplenomegaly. In view of the persistent high fever, specimens
were obtained for serum antibodies to B burgdorferi, E chaffeensis,
and the HGE agent, as well as for PCR testing for the 2 causative
agents of human ehrlichiosis. The patient was admitted to the
hospital.
The next day, the white blood cell count was 8900/mm3 (68%
neutrophils, 26% lymphocytes, and 6% monocytes), the platelet
count was 298 000/mm3, and an abdominal ultrasound re-
vealed fluid-filled loops of bowel in the right lower quadrant
without any free fluid. Intravenous ceftriaxone therapy was
initiated. On the third hospital, day the fever, abdominal pain,
and distension persisted, and guarding and rebound were
noted on abdominal palpation. A repeat abdominal CT scan
with oral contrast showed distended loops of small and large
bowel without any masses or free fluid. In view of a concern
about a possible perforated appendix, an exploratory laparot-
omy was performed. At surgery, mild nonspecific serositis of
the vermiform appendix was found along with a 7-mm lymph
node, which subsequently was reported to show nonspecific
reactive changes. Postoperatively, her electrolytes and liver
function tests were normal (AST: 38 U/L; ALT: 31 U/L), but the
white blood cell count had decreased to 3600/mm3 (69% neu-
trophils, 29% lymphocytes, and 2% monocytes) and the platelet
count was 195 000/mm3. The following day (hospital day 4),
the New York State Department of Health laboratory reported
that the PCR was positive for the presence of HGE agent 16s
rDNA and negative for E chaffeensis. Treatment with doxycy-
cline was started and the patient was afebrile the next day.
Subsequently, the acute polyclonal IFA for E equi was reported
as nonspecific, but a convalescent specimen obtained 23 days later
was positive, with a titer of 320. Four months after the hospital-
ization the patient was well. At that time her IFA for E equi
immunoglobulin G (IgG) was positive (1:512), but the immuno-
globulin M (IgM) was negative (,1:20). Both IgG and IgM IFA
titers for E chaffeensis were negative.
DISCUSSION
This case has several unusual features. First, to our
knowledge, this the youngest patient reported with
documented HGE.4,5 The diagnosis was confirmed
by the elevated IFA to E equi, the positive PCR for the
HGE agent, and the increase in IFA E equi IgG titer
between the acute and convalescent specimens. The
vast majority of cases of HGE have been reported in
adults, with very few diagnosed during the first 2
decades of life. This is in sharp contrast to Lyme
disease, in which the incidence is much higher in
children than adults. There is no clear explanation
for this age discrepancy, despite the fact that the
same vector spreads the agents that cause both HGE
and Lyme disease.
Second, although many of the patient’s symptoms
were typical for HGE, there have been no previous
reports of HGE mimicking acute abdominal pain in
any age patient. In fact abdominal symptoms are
unusual, although Wallace et al5 did report 3 patients
with gastrointestinal hemorrhages.
Finally, our patient did not manifest the spectrum
of laboratory abnormalities typically seen in adults
with HGE.6 She did have leukopenia, but her platelet
count remained normal and she had only a minimal,
transient increase in her AST. Once other young
patients with HGE are reported, it will be interesting
to see whether the clinical presentations are different
in children and whether they develop the character-
istic laboratory abnormalities noted in older patients.
If HGE is suspected, prompt treatment with doxycy-
cline is indicated, pending laboratory confirma-
tion.9,10
Jeffrey C. Gershel, MD
Department of Pediatrics
Jacobi Medical Center
Albert Einstein College of Medicine
Bronx, NY 10461
REFERENCES
1. Bakken JS, Dumler S, Chen SM, Eckman MR, Van Etta LL, Walker DH.
Human granulocytic ehrlichiosis in the upper Midwest United States: a
new species emerging? JAMA. 1994;272:212–218
2. Chen S-M, Dumler JS, Bakken JS, Walker DH. Identification of granu-
locytopenic Ehrlichia species as the etiologic agent of human disease.
J Clin Microbiol. 1994;32:589–595
3. Westchester County Department of Health. Infectious Disease Update:
Tickborne Diseases. New Rochelle, NY: Westchester County Department
of Health; 1998
4. Jacobs RF, Schutze GE. Ehrlichiosis in children. J Pediatr. 1997;131:
184–191
EXPERIENCE AND REASON 603
 at Erasmus Rotterdam on November 29, 2006 www.pediatrics.orgDownloaded from 
5. Wallace BJ, Brady G, Ackman DM, et al. Human granulocytic ehrlichio-
sis in New York. Arch Intern Med. 1998;158:769–773
6. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K,
Dumler S. Clinical and laboratory characteristics of human granulocytic
ehrlichiosis. JAMA. 1996;275:199–205
7. Edelman DC, Dumler JS. Evaluation of an improved PCR diagnostic
assay for human granulocytic ehrlichiosis. Mol Diagn. 1996;1:1–49
8. Centers for Disease Control. Statewide surveillance for ehrlichiosis—
Connecticut and New York 1994–1997. MMWR Morb Mortal Wkly Rep.
1998;47:476–480
9. Fritz CL, Glaser CA. Ehrlichiosis. Infect Dis Clin North Am. 1998;12:
123–136
10. Dumler JS, Bakken JS. Human ehrlichioses: newly recognized infections
transmitted by ticks. Annu Rev Med. 1998;49:201–213
NO HELP IN SIGHT FOR THE POOR
With globalization, goods, capital, culture, and knowledge readily diffuse across
borders, but political and social institutions often lag a step behind. Among
populations increasingly interconnected, infectious spill over borders but afflict the
poor and excluded disproportionately. For those less fortunate, the boundaries
seem only semipermeable to the drugs and technologies that are life-saving . . . and
the benefits of globalization may come late, or not at all.
So A. Tackling the roots of health inequality. Lancet. 2000;355:504–505. Book review
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